Skip to main content
. 2021 Nov 3;26:1351–1363. doi: 10.1016/j.omtn.2021.10.028

Figure 5.

Figure 5

EZH2 epigenetically silenced Wnt2 expression

(A) The expression of Wnt2 was determined by qRT-PCR after ectopic expression of several epigenetic regulators (n = 4). (B) The protein level of Wnt2 was determined by western blotting (n = 4). (C) Left: illustration of ChIP primer design within Wnt2 proximal promoter. Right: ChIP assay showed enrichment of EZH2 on Wnt2 promoter (n = 4), and GAPDH antibody was used as a negative control. (D) ChIP assay data showed enrichment of H3K27me3 modification on Wnt2 promoter (n = 4), and GAPDH antibody was used as a negative control. (E) The RNA level of Wnt2 after treatment with EZH2 inhibitor DZNep (n = 4). (F) The expression of Wnt2 was determined by qRT-PCR assay after treatment with DZNep (n = 4). (G) ChIP assay showed enrichment of EZH2 on Wnt2 promoter after treatment with DZNep (n = 4), and GAPDH antibody was used as a negative control. ∗∗p < 0.01; ∗∗∗p < 0.001.